| Prevention of left ventricular remodelling after acute myocardial infarction: an update. | |
| | |
MedLine Citation:
|
PMID: 20874671 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Left ventricular remodelling is a progressive process, which starts immediately after acute myocardial infarction and evolves in the chronic phase of heart failure. It is characterized by left ventricular chamber dilatation and increased wall stress, which results in alteration of the contractile properties of the non-infarct zone and impairment of the systolic and diastolic performances of the left ventricle. Neurohormonal activation and increased sympathetic stimulation are among the factors that have been linked to the development and progression of left ventricular dysfunction after acute myocardial infarction. The present review will address recent insights from new patents and experimental studies of drugs, which ought to prevent left ventricular remodelling. Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Beta-Blockers have been proven effective in modulating the process of remodelling and in reducing the occurrence of adverse events. However, in most of the trials high risk patients have been excluded, and uncertainty still exists regarding a number of clinically relevant questions. Data from experimental studies have identified new targets for interventions to prevent reverse left ventricular remodelling, i.e. stem cell transfer, activation of cardiac and leukocyte-dependent oxidant stress pathways, inflammatory pathway activation, matrix-metalloproteinase activation. |
| | |
Authors:
|
Roberta Rossini; Michele Senni; Giuseppe Musumeci; Paolo Ferrazzi; Antonello Gavazzi |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Recent patents on cardiovascular drug discovery Volume: 5 ISSN: 2212-3962 ISO Abbreviation: Recent Pat Cardiovasc Drug Discov Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-15 Completed Date: 2011-02-22 Revised Date: 2011-11-10 |
Medline Journal Info:
|
Nlm Unique ID: 101263805 Medline TA: Recent Pat Cardiovasc Drug Discov Country: United Arab Emirates |
Other Details:
|
Languages: eng Pagination: 196-207 Citation Subset: IM |
Affiliation:
|
Dipartimento Cardiovascolare, Ospedali Riuniti di Bergamo, Bergamo, Italy. roberta_rossini@yahoo.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
pharmacology,
therapeutic use Aldosterone Antagonists / therapeutic use Angiotensin Receptor Antagonists / pharmacology, therapeutic use Angiotensin-Converting Enzyme Inhibitors / pharmacology, therapeutic use Antioxidants / therapeutic use Enzyme Activators / pharmacology, therapeutic use Heart Failure / physiopathology, prevention & control Humans Hypertrophy, Left Ventricular / etiology*, physiopathology, prevention & control* Matrix Metalloproteinases / metabolism Myocardial Infarction / complications*, drug therapy*, physiopathology, prevention & control Stem Cell Transplantation Ventricular Function, Left / drug effects Ventricular Remodeling / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Aldosterone Antagonists; 0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antioxidants; 0/Enzyme Activators; EC 3.4.24.-/Matrix Metalloproteinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cryoballoon ablation of atrial fibrillation: state of the art 10 years after its invention.
Next Document: Angiogenesis and the heart.